Biopharma Royalty Powerhouse Dips Despite Beat-And-Raise Quarter

Ligand stock slipped early Thursday after the royalty powerhouse reported better-than-expected earnings and sales.

Investors Business Daily • Aug 6, 2026

Ligand Pharmaceuticals Q2 Earnings Call Highlights

Ligand Pharmaceuticals NASDAQ: LGND reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering.

MarketBeat • Aug 6, 2026

Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

This Stock Of The Day Rides Big Pharma Royalties; It's Up 56% In 2026

LGND stock has risen more than 56.5% so far in 2026. Ligand doesn't make drugs; it forks over funding in exchange for Big Pharma royalties.

Investors Business Daily • Jul 27, 2026

Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026

JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026.

GlobeNewsWire • Jul 23, 2026

XOMA Royalty Announces Closing of Its Acquisition by Ligand

EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisition of XOMA Royalty.

GlobeNewsWire • Jul 14, 2026

Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

Acquisition adds seven  commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term opportunities to drive growth Ligand to provide updated 5-year outlook during Investor Day on December 8, 2026 JUPITER, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has completed its acquisition of XOMA Royalty Corporation (“XOMA Royalty”), a biotechnology royalty aggregator, for $39.00 per share of common stock in cash, for a total equity value of approximately $739 million.

GlobeNewsWire • Jul 14, 2026

3 Overlooked Stocks Positioned for the Next Market Rotation

Tech has carried this market for years, but it isn't the only game left running. Small caps are outperforming in 2026, the Magnificent Seven have cooled, and money is starting to spread into corners of the market that retail investors rarely check.

MarketBeat • Jul 13, 2026

Ligand Pharma: Expect Bright And Exciting Future For This Growing Royalty Aggregator

Ligand Pharmaceuticals has delivered exceptional long-term returns, rising from ~$86 to nearly $300 over six years. Recent developments include a significant Xoma acquisition and portfolio advancements. I closely review LGND's Q1 2026 earnings, highlighting operational and financial performance and strategic moves.

Seeking Alpha • Jul 1, 2026

Ligand Announces Closing of Convertible Senior Notes Offering

Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand's common stock upon conversion of the notes JUPITER, Fla., June 25, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its previously announced offering (the “offering”) of 0.00% convertible senior notes due 2031 (the “notes”).

GlobeNewsWire • Jun 25, 2026